However, in a stratified analysis separately considering patients with and without NSCLC, the high expression of PD-L1 was not significantly different between KRASG12C and KRASnon-G12C mutations in either NSCLC (OR = 1.16, FDR-P = .38) or non-NSCLC tumors (OR = 1.01, FDR-P = .95), suggesting that the significant association between PD-L1 and KRASG12C observed in all cancers was likely due to coenrichment in NSCLC. The gene discussed is CD274; the disease is cancer.